On May 9, the Institute for Gene Therapy (IGT), along with the Alliance for Regenerative Medicine (ARM), held a Congressional briefing featuring patient and policy perspectives focused on the Centers for Medicare and Medicaid Services’ (CMS) recently proposed changes to the Medicaid Drug Rebate Program (MDRP).
If implemented, the changes to MDRP will have a negative impact on some of our country’s most vulnerable patients and future innovation for cell and gene therapy. Addressing these challenges is essential as we work to bring transformative gene therapies to patients and families living with unmet medical needs and to fortify an infrastructure that supports sustainable delivery of transformative gene therapies.
Speakers included:
Erik Paulsen, Chairman, Institute for Gene Therapies
Amanda Krzepicki, Policy Director, Autoimmune Association
Madelyn Schloss, Gaucher Community Alliance
Kim Phelan, Hemophilia B Coalition
Erica Cischke, Vice President of Government Affairs, Alliance for Regenerative Medicine
John Feore, Policy Director, Institute for Gene Therapies
Watch the discussion here: